Rio Tinto has committed to a new four-year partnership with Lifeline WA, as the crisis support organisation predicts it will need more than 700 volunteers by 2030.
WA's deputy chief health officer Clare Huppatz has taken over from retired Andrew Robertson as the state's chief health officer, becoming the first female in the role.
A Perth regenerative medicine company has revealed a humanitarian shipment of its nerve repair products have been used in 23 surgical procedures on injured Ukrainian soldiers.
A world-first antipsychotic injectable drug developed in Perth will accelerate its path to market after the company behind it, Reliis, was acquired by a Melbourne biotechnology developer.
Retirement living village operators have expressed concerns a lack of clarity on the timing of state reforms puts the progress of crucial developments at risk.
Linked Support Solutions has been pulled out of administration by its sole director after the disability support services provider succumbed to financial losses and NDIS registration woes.
Two of the key players in the development of a children's hospice in Swanbourne, former premiers Mark McGowan and Mike Baird, have toured the construction site for the first time.
A state planning committee has approved an expansion of the Osborne Park hospital, as part of the next stage of the $1.8 billion Women and Babies Hospital project.
Shares in Botanix have dropped more than 40 per cent after the West Perth biotech announced a $45 million capital raising, but at a significant discount to its last traded price.
The WA company behind an imaging device which can reduce the number of repeat surgeries for breast cancer patients has received $27 million in a private funding round to support its push to US FDA approval.
Treatments from an innovative Perth healthcare company offering novel MDMA and psilocybin-assisted therapy for PTSD will be covered by insurance in three states, after it expanded an agreement with Medibank.
A plan to transition the operator of Mount Hospital to a not-for-profit has been backed by its receivers, in a move which would see 31 hospitals nationwide follow suit.
A company born out of UWA research and seeking to provide a circuit breaker to antimicrobial resistance will look to raise $28 million as it nears a crucial juncture of the preclinical stage.
Perth biotech PYC Therapeutics will go to market seeking $653 million to advance four of its treatments through early trial stages and towards their first transaction.The Nedlands-based ASX-list
WA's medicinal cannabis industry has notched another win for the week, with Zelira Therapeutics attaining $33 million in non-dilutive funding for its cannabis-based autism treatment.
Argent Biopharma has streamlined its asset acquisition of fellow WA cannabis player AusCann, while another Perth player has been subject to a reverse takeover.
Perth-based Argenica Therapeutics has partnered with an Oxford University AI spinout to evaluate the effectiveness of its flagship ARG-007 stroke drug, finding previously hidden impacts.
